<DOC>
	<DOCNO>NCT01695759</DOCNO>
	<brief_summary>To evaluate clinical efficacy immunogenicity drug test Eritromax ® - ( rHuEPO Blau ) compare drug Eprex ® ( Janssen-Cilag rHuEPO ) treatment patient anemia secondary chronic kidney disease ( CKD ) , correction assess change hemoglobin level .</brief_summary>
	<brief_title>Clinical Efficacy Two Erythropoietin Drug Participants With Secondary Anemia Chronic Kidney Disease .</brief_title>
	<detailed_description>Data assess secondary efficacy drug test drug comparison evaluating : - Maintenance hemoglobin level ( baseline vs. end treatment ) maintenance phase ; - Dose EPO necessary repair maintenance ; - Need transfusion ; - Safety study drug type , frequency intensity adverse event 12 month follow . objective exploratory - evaluate immunogenicity drug quantification anti-erythropoietin every six month .</detailed_description>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>. Confirm voluntary participation agree purpose study sign date IC two way ; b . Male female , regardless race social class ; c. Age 18 60 year ; d. Bearer dialysisdependent CKD ( hemodialysis peritoneal dialysis * ) ; . Present clinical diagnosis anemia , characterize hemoglobin level &lt; 10g/dL start study ; f. Adequate dialysis : Kt / V ≥ 1.2 hemodialysis patient ≥ 1.8 patient peritoneal dialysis ( base calculation Daugirdas II ) ; g. Display adequate iron store ( TSAT &gt; 20 % serum ferritin &gt; 100ng/ml ) prior initiation treatment erythropoietin 1 . Participation clinical trial 12 month precede survey ; 2 . Patients uncontrolled hypertension , average 180/100mmHg require hospitalization last 6 month ; 3 . Presence cause anemia CRD , bleeding , hemolysis , pernicious anemia hemoglobinopathy ; 4 . Patients present change clinical abnormality , qualify interfering change , severe hyperparathyroidism ( iPTH &gt; 1000 pg / mL ) , severe congestive heart failure ( NYHA Class IV ) , acute myocardial infarction within last 3 month , active neoplasia followup , severe liver disease , active infection ( leukocyte change ) , history aluminum toxicity schedule surgery , pregnancy lactation ; . Patients know hypersensitivity component formulation product derive mammalian cell ; f. Prior therapy erythropoietin less 3 month ; g. Realization transfusion le 3 month ; h. Any situation discretion Principal Investigator interfere study data .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Anemia Secondary</keyword>
	<keyword>Chronic Kidney Disease</keyword>
</DOC>